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 31 
Synopsis 32 
 33 
Retinal detachment in eyes with Boston keratoprosthesis seems to have specific characteristics and the visual acuity remains poor 34 
despite successful anatomical results. 23 gauge vitrectomy can be effectively performed in these patients. 35 
 36 
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 47 
Abstract 48 
Purpose: To review the incidence and features of vitreoretinal complications of a permanent Boston keratoprosthesis and to report 49 
the use and outcomes of 23-gauge vitrectomy to manage vitreoretinal pathology.  50 
Design: Retrospective non comparative, interventional case series. 51 
Subject, Participants: 27 eyes of 27 patients managed with a Boston Keratoprosthesis at Moorfields Eye Hospital over a three-52 
year period.  53 
Methods: All eyes that underwent pars plana vitrectomy (PPV) and had at least 6 months follow-up were analysed with a specific 54 
focus on the anatomical and histological characteristics of retinal detachment and outcomes of surgery.  55 
Main Outcomes Measures: Anatomical success and characteristics of retinal detachment over the follow-up period. 56 
Results: 27 patients underwent Boston Keratoprosthesis implantation over the study period. Of these 6 (22%) required PPV for 57 
retinal detachment which demonstrated a specific pattern of serous elevation with subsequent severe anterior proliferative 58 
vitreoretinopathy. The mean follow up period was 9 months (range 6-14 months). At final follow-up visual acuity ranged from PL to 59 
6/18 and 5 of 6 cases had attached retinae under the silicone oil. Histological analysis of a subretinal membrane demonstrated a 60 
predominatly glial / RPE fibrocellular tissue consistent with proliferative vitreoretinopathy (PVR). 61 
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Conclusion: The study showed that retinal detachment complicated by PVR, as demonstrated by the clinical and histological 62 
characteristics of  this condition, is common in patients undergoing Boston Keratoprosthesis. We also showed that 23 gauge 63 
vitrectomy can be effectively performed in patients with a permanent prostesis. Visual acuity often remains poor despite successful 64 
anatomical results.   65 
 66 
67 
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 68 
Introduction 69 
Use of the Boston Type 1 keratoprosthesis has increased since its approval by the Food and Drug Administration (FDA) in 1992, 70 
and its recent CE mark. It is a viable alternative to corneal transplantation in eyes with a poor prognosis for penetrating keratoplasty 71 
including severe ocular surface disease (cicatricial pemphigoid, Stevens-Johnson syndrome, stem cell deficiency, chemical burns) 72 
or repeated corneal graft failure. [1-3] There have been continuing refinements of the anterior segment surgical techniques as well 73 
as an increasing experience in the management of complications in patients requiring Boston keratrosthesis. This has highlighted 74 
the need for vitreoretinal expertise in the management of posterior segment complications.  75 
 Vitreoretinal surgical management of posterior segment disease in eyes with Boston KPro has been previously reported, [4-76 
6] – this has focused on the vitreoretinal techniques involved. To date, there has been a systematic report of case series which 77 
documents the incidence of posterior segment complications. [7] However, the specific clinical and immunohistological 78 
characteristics of retinal detachment in the setting of Boston Kpro have not been examined.    79 
 The purpose of this study was to review the incidence and features of vitreoretinal complications in a consecutive cohort of 80 
patients with a permanent Boston keratoprosthesis, to report clinical features of posterior segment complications and the operative 81 
management of these using 23-gauge vitrectomy and to examine the characteristics of a subretinal membrane surgically excised 82 
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from an eye complicated by PVR retina following the procedure . Additionally, the anatomical and functional outcomes are reported 83 
in relation to the presenting and secondary pathology.  84 
 85 
Patients and Methods 86 
Moorfields Eye Hospital Research Management Committee (RMC) approval was obtained for this study. We conducted a 87 
retrospective chart review of the patients implanted with Boston Keratoprosthesis at Moorfields Eye Hospital over a period of three 88 
years as identified from the anterior segment service database. All eyes that underwent a 23 gauge pars plana vitrectomy (PPV) 89 
and had at least 6 months follow-up were included in the analysis. Data were collected on  demographic characteristics, the corneal 90 
pathology for which the eyes required  keratoprosthesis implantation, the best corrected visual acuity (BCVA) pre and post 91 
keratoprosthesis, the number of previous grafts, pre-existing  glaucoma or other ocular co-morbidity, and previous glaucoma 92 
surgical intervention. Data on posterior segment pathology requiring surgical intervention, the BCVA pre and post PPV and the 93 
intraoperative characteristics of posterior segment pathology and  post-operative complications were also collected. 94 
 95 
 96 
 97 
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 98 
Surgical Technique 99 
Pars Plana Vitrectomy was performed in all cases using 23 gauge valved trocars placed as anteriorly as possible (i.e at the limpus) 100 
using 4-mm infusion cannulae. The binocular indirect ophthalmo-microscope (BIOM) was used as a viewing system. As a default, 101 
the wide field BIOM lens was used and on some occasions the 90 diopters (0.4) BIOM lens was used if needed (see results and 102 
discussion section). Perflouro-n-Octane (perlfruoron, Alcon Laboratories, Watchmore Park, Riverside Way, Camberley GU15 3YL, 103 
UK), silicone oil (1300 centistokes, Bausch & Lomb U.K., Ltd, Surrey KT2 6TN, England) and membrane blue-dual® (D.O.R.C, 3214 104 
VN Zuidland, The Netherlands) for epiretinal membrane staining were used where appropriate. 105 
 106 
 107 
 108 
Histological examination of subretinal membrane  109 
A subretinal membrane excised during vitrectomy (patient 5, Table 1,2) was fixed in 4% paraformaldehyde in Phosphate-bufferred 110 
saline (PBS, pH 7.2),  cryoprotected in 30% sucrose and embedded in OCT (Optimum Cutting Temperature compound) prior to 111 
cryostat sectioning. Sections 12µm thickness were immunostained using our publishedprotocols. [8] Briefly, sections were 112 
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incubated overnight at 4°C with primary antibodies, following by three 10 min washes in Tris-buffered saline (TBS, pH 7.5).  113 
Specific binding of primary antibodies was detected using donkey anti-IgG labelled with AlexaFluor 448 or AlexaFluor 555 114 
(Molecular Probes, Invitrogen) reacting the species in which the primary antibody was raised, for 2 h at room temperature. Slides 115 
were then washed three times as above, counterstained with 4_,6_-diamino-2-phenylindole (DAPI) for 1 minute and covered with 116 
glass coverslips using Vectashield mounting medium (Vector Laboratories, Burlingame, CA). Fluorescent images were recorded 117 
using a confocal microscope (LSM 710; Carl Zeiss, Oberkochen, Germany) operating in multitrack mode for Alexa 488, 555 and  118 
DAPI fluorochromes.  Primary antibodies used in the study included antibodies to i) the intermediate filament protein glial fibrillary 119 
acid protein (GFAP, a marker of reactive gliosis) (DAKO, UK; 1:50 dilution), ii) Cellular retinaldehyde binding protein (CRALBP, a 120 
Müller glia and RPE cell marker) (Santa Cruz, USA; 1:200 dilution), iii) Cytokeratin 8/18 (RPE cell marker) (Dako, UK). Isolectin B4 121 
(a microglia and endothelial cell marker) (Life technologies, UK; 1:200 dilution) and CD68 (a macrophage and RPE cell surface 122 
marker) (DAKO, UK; 1:50 dilution).  123 
 124 
Results 125 
Overall, 27 patients underwent Boston Keratoprosthesis implantation over a period of three years. Of these, 6 required pars plana 126 
vitrectomy (22.2%), Table 1. The mean age of the patients who underwent PPV was 63.8 years with a male to female ratio of 5:1, 127 
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respectively. The mean follow up period was 9 months (range, 6-14 months).. The baseline (prior to vitrectomy) best-corrected 128 
visual acuity ranged between perception of light (PL) to 6/36.   129 
 In the majority of patients (5 out of 6 cases) the posterior segment pathology that required vitrectomy followed a specific 130 
pattern. Anterior proliferation was observed from the KPro to the ciliary body/anterior retina causing anterior (retro-prosthesis) 131 
membrane formation and contraction. Hypotony was noted in these cases although the exact intraocular pressure and the time 132 
course of the hypotony was difficult to assess with the KPro in situ. These features were combined with extensive serous/tractional 133 
anterior retinal detachment with co-existent aggressive subretinal and epiretinal proliferation. Intraoperatively, no pre-existing retinal 134 
breaks were identified in these patients. One patient (case 4) required vitreoretinal intervention for the management of a blocked 135 
Baerveldt tube (posteriorly placed). 136 
 In four cases, silicone oil was used (case 1,2,5 and 6). In one case the retina failed to re-attach intraoperatively after 137 
extensive membrane peeling due to extensive PVR with epiretinal and subretinal PVR membranes (case 3). Perluoro-N-octane 138 
was used and it exchanged wih silicone oil.One case required three vitreoretinal procedures (including  inferior retinectomy, 139 
endolaser and silicon oil injection during the last procedure) for retinal re-attachment due to recurrent  PVR  (epiretinal and 140 
subretinal membranes) 7 months following the initial vitreoretinal intervention (case 2). In all procedures extensive peeling of the 141 
pre and sub-retinal PVR membranes and bands was performed. Notably in one case the BIOM widefield lens failed to provide 142 
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adequate focus on the posterior pole and the 90 diopters BIOM lens had to be used for the entire length of the vitreoretinal 143 
procedure (case 3).  144 
 In two cases ( 3 and 5) with total retinal detachment and retroprosthetic membrane, although the trocars had been anteriorly 145 
placed at the limbus, pre-operative anterior displacement of the retina resulted in sclerotomies passing initially subretinally and then 146 
through retinal tissue  to the vitreous cavity. The BCVA at the last follow-up ranged from NPL to 6/60 and apart from case 3, all 147 
cases demonstrated attached retinae under the silicon oil at the last follow-up visit.  All data and additional comments are 148 
summarized in Table 1 and Table 2. 149 
 150 
 151 
 152 
 153 
 154 
 155 
 156 
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 159 
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 161 
 162 
 163 
 164 
 165 
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 166 
Table 1. Presenting Characteristics of patients with Boston K-Pro who underwent vitreoretinal surgery for retinal 167 
detachment. 168 
 169 
  170 
N Age Sex Pre-Kpro Diagnosis 
Pre Kpro 
VA 
Number of previous 
grafts 
Glaucoma 
Sx 
Ocular co-
morbitity 
Post K-Pro 
VA 
1 47 M SJS CF 7 None None 6/12 
2 64 M Chemical injury HM 1 None None 6/6 
3 85 M 
Aniridia+post ICCE 
aphakia 
HM 2 Tube chronic CMO 6/6 
4 25 M KC HM 2 None None 6/9 
5 80 M Penetrating trauma HM 4 Tube glaucoma/BRVO 1/60 
6 82 F Failed grafts PL 6 Tube TRD 6/60 
 171 
SJO=Sjogren syndrome, ICCE=intracapsular cataract extraction, KC=Keratoconjunctivitis Sisca, CF=Counting Fingers, HM=Hand 172 
Movement 173 
PL=Perception of Light, CMO=cystoid macular oedema, BRVO=Branch retinal Vein Occlusion, TRD=Tractional Retinal 174 
Detachment 175 
 176 
 177 
 178 
 179 
 180 
 181 
  182 
 183 
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 184 
Table 2. Posterior segment pathology, Surgical Management and Outcomes 185 
 186 
N Posterior segment complication 
Pre VR 
VA 
KPro to VR (m) VR procedure 
End 
VA 
FU 
(m) 
1 TRD CF 4  V/ILM+ERM peel/L/C/SO 6/60 9  
2 ERM/TRD and High IOP HM 
8 months then second 
PPV/PEEL 6months 
LATER then  third 
PPV/RETINECTOMY/OI
L 6 weeks later then  
V/peel/L/posterior tube CF     24   
3   
RP membrane/open funnel RD+epi and 
subretinal PVR 
HM 8  
tube removal/ V/ 360 retinectomy/ SRB 
removal 
PL 7  
4 
High IOP/required Baerveld tube 
posterior+Vitrectomy 
6/36 
1 month then second 
PPV/cryo/gas   4 months 
later and third  
PPV/RETINECTOMY/OI
L 3 months 
later(MULTIPLE 
GLAUCOMA 
PROCEDURES FOR 
MALIGNANT 
GLAUCOMA)   
Vitrectomy/Baervelt tube insertion NPL 14 
5 
RPM membrane/hypotony/choroidal 
effusion/TRD 
HM 6  Vitrectomy/L/silicon oil HM 8  
    TRD+RRD PL 9  combined KPro/V/retinectomy/L/SO HM 13 
 187 
VR=Vitreoretinal 188 
 189 
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 190 
Immunohistochemical features of the subretinal membrane  191 
Immunohistochemical analysis of the subretinal membrane examined showed that this had the distinctive characteristics of a PVR 192 
membrane. This was demonstrated by its intense staining for GFAP and CRALBP, indicative of retinal glial cells..  In addition, a 193 
dense infiltration of RPE cells was also observed, as judged by the strong staining for cytokeratin 8/18 staining.  Intense staining for 194 
Isolectin  B4 and CD68 was was also observed, indicating severe microglia and macrophage infiltration of the subretinal 195 
membrane. (Fig 1). These observations are consistent with previous reports of PVR subretinal membranes [9,10] 196 
 197 
Discussion 198 
 The worldwide clinical experience of the use of Boston Keratosprosthesis has increased and several modifications of the device 199 
have resulted in better retention and lower complication rate. [11] There are, however, a number of significant complications 200 
occurring in eyes which have undergone Boston KPro implantation including retroprosthetic  membrane (RPM), [1,7,11] vitritis, [12] 201 
endophthalmitis, [7,12] prosthetic failure, [1] epiretinal membrane, [7] vitreous haemorrhage, [7]  choroidal detachment, [7]  and 202 
retinal detachment. [4-7].  In our series, a significant incidence (22.2%) of posterior segment pathology (retinal detachment) 203 
requiring surgical management was noted.  In the majority of patients (5 out of 6 cases) we observed a specific pattern of very 204 
 15 
 
severe retinal detachment which resulted in profound vision loss. We noted that the eyes were hypotonous with characteristic 205 
anterior proliferation causing traction to the ciliary body and anterior retina. This resulted in extensive and significant tractional 206 
retinal detachment with significant epi- and sub-retinal proliferative vitreoretinopathy (PVR) in all cases. It was notable that no 207 
retinal breaks were identified intraoperatively.  208 
Although the histological features of retroprosthetic membranes have been previously reported, the characteristics of 209 
subretinal membranes excised from eyes complicated by PVR following Boston KPro implantation have not been documented.  210 
Unlike the negative staining for pan-cytokeratine observed in retroprosthetic membranes [Stacy RC et al- PMID 21402987], our 211 
study showed that the subretinal membrane examined exhibited a strong staining for cytokeratines 8/18, well known markers of 212 
RPE cells [Hiscott et al- PMID  12101446]. In addition, strong immunoreactivity for GFAP and CRALBP, which are markers of 213 
Müller glia and indicative of reactive retinal gliosis, was also seen.  Microglial and macrophage infiltration, as judged by the intense 214 
immunostaining for isolectin B4 and CD68 was also demonstrated, which is again consistent with the inflammatory nature of PVR 215 
membranes [Charteris et al- PMID 8094546]. These observations are consistent with previous reports of PVR subretinal 216 
membranes [9,10] and confirm that a strong inflammatory response can be also elicited by Boston K-Pro implantation within the 217 
retina, leading to an aggressive PVR response to retinal detachment secondary to the implant procedure.  218 
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 Performing posterior segment surgery in these patients can be challenging and the information regarding the type of 219 
posterior segment pathology, the intraoperative techniques and expectations, as well as the post-operative management and 220 
prognosis have been brief in previous reports . [4-6] Kiang et al, [5] reported on their experience from the use of small gauge 221 
vitrectomy (23 procedures) in 14 eyes. Of them, 7 were performed at the time of KPro placement, 1 included KPro removal and one 222 
was an exploratory endoscopy prior to KPro placement. In their series, the indication for PPV was the presence of RPMs in 7 cases 223 
and retinal detachment in 6 cases. The authors have concluded that small gauge vitrectomy can be effectively used for patients 224 
with permanent KPro.  More recently, Harissi-Dagher et al, [6] reported on the outcomes from the use of 20 gauge PPV (modified 225 
technique as described by Stanescu-Segall et al, [13]) in 5 cases. Retinal detachment was the primary indication in 4 cases and 226 
suprachoroidal haemorrhage from glaucoma tube overfiltration in one case. The authors concluded that PPV through KPro is a 227 
viable approach butthe visual outcome remains poor.  228 
 In our study, 23 gauge vitrectomy with valved trocars was used in all cases. We believe that the use of valved trocars is 229 
important in these cases given the complexity of the previous history and the higher risk for intraoperative choroidal 230 
detachment/haemorrhage predisposed by intraoperative intraocular pressure fluctuations.  In all cases, the trocars were placed as 231 
anteriorly as possible (ie at the limbus) to ensure that the sclerotomies were performed at the pars plana. However, in two cases 232 
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pre-operative anterior displacement of the retina resulted in sclerotomies passing through retinal tissue in order to gain access to 233 
the posterior pole. This occurrence highlights the distinct pattern of retinal detachment that was observed in our series.  234 
  All the patients in our series with retinal detachment demonstrated a variable degree of retroprosthetic membrane (RPM). It 235 
is possible that simultaneous PPV at the time of the KPro placement as suggested by Kiang et al, [5] may play a role in decreasing 236 
the incidence of anterior proliferation, nonetheless it may add a new set of possible complications to an already complex procedure. 237 
In addition, one of our cases (case 5) with significant tractional retinal detachment and anterior proliferation had previously 238 
undergone vitrectomy. As demonstrated in the results section and Table 2, the BCVA at the last follow up visit ranged from 6/60 to 239 
NPL, emphasizing the poor prognosis of patients with Boston Kpro requiring vitreoretinal intervention. In the future the use of a 240 
titanium back plate for the KPro might assist in reducing RPM occurrence. It is also notable that in our series three of the six 241 
patients with severe anterior traction and retinal detachment had previously had glaucoma drainage tube surgery. This may have 242 
contributed to ongoing anterior proliferation either through low grade inflammation and blood ocular barrier breakdown or potentially 243 
because of chronic hypotony (which may be undiagnosed because of the presence of the KPro) contributing to the observed 244 
anterior serous retinal detachment. Two patients in our series had a drainage tube placed at the time of vitreoretinal surgery. 245 
 In our series, all vitreoretinal maneuvers were performed without difficulty through the 23 gauge valved system with the use 246 
of BIOM as a viewing system. It is interesting that in one case we failed to achieve a good focus of the retina using the wide-field 247 
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lens and the surgeon had to use the 90 diopters BIOM lens for the full length of the procedure. In this case all surgical steps 248 
including fluid-air exchange, use of PFCL, retinectomy, membrane removal and dissection, cryotherapy/endolaser retinopexy and 249 
injection of silicon oil were performed using the 90 diopter lens.  250 
   251 
 Our study has limitations due to its retrospective nature and the relatively small number of cases with retinal detachment. 252 
Nevertheless we have identified a typical pattern of severe retinal detachment in eyes with a permanent Boston KPro, with anterior 253 
proliferative vitreoretinopathy extending from the Krpo and we have demonstrated the results of the histological examination of a 254 
subretinal membrane in one of our patients. .  We also report our experience in managing vitreoretinal complications in this group of 255 
patients. 256 
 In conclusion, 23 gauge vitrectomy can be effectively performed in patients with permanent Boston KPro. Retinal 257 
detachment in these cases seems to have specific characteristics and the visual acuity remains poor despite successful anatomical 258 
results. Further studies are needed to explore ways of reducing and better treating post KPro retinal detachment.  259 
 260 
 261 
 262 
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Legend to Figure 277 
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Confocal microscopy images of subretinal membrane showing immuno-positivity for the reactive glial marker GFAP (A), the Müller 278 
cell marker CRALBP (B), cytokeratin 8/18, a marker of RPE cells (C), isolectin B4, a marker of endothelium and reactive microglia 279 
(D) and the macrophage/microglia marker CD68 (E). Cell nuclei stained with DAPI (blue). Images on the left show the 280 
corresponding section stained with H&E. Scale bars: 50μm (images A,B and C) and 100μm (images D and E).  281 
 282 
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